Saxenda day 2 nausea claims: what GLP-1 side effects actually look like
Quick answer
Kelly is in the first week of a Saxenda (liraglutide) titration at the starting dose of 0.6 mg daily, the lowest rung of a multi-month escalation schedule that targets 3.0 mg for weight management. She reports nausea onset consistent with the known GI side effect profile of GLP-1 receptor agonists, which is most pronounced in early titration and at each dose increase. Her plan to combine liraglutide with cardiovascular exercise is aligned with clinical guidance, as exercise during GLP-1 therapy has been associated with better preservation of lean mass during weight loss.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @kellyramirez30 actually say?
On day two of restarting Saxenda (liraglutide 0.6 mg), Kelly reported mild nausea that she was managing with "snacks and food," noticed early appetite reduction, switched injection sites to her arm for the first time, and committed to pairing the medication with jogging. She was clear that she does not want to "fully rely" on the medication and sees it as a tool, not a cure.
She did not make dramatic weight loss claims, did not advise anyone on dosing, and did not promote any specific product. For a day-two GLP-1 video, the framing was more grounded than most of what circulates under the #glp1community hashtag.
Does the science back this up?
Mostly, yes. The nausea timeline and the strategy she is using to manage it are consistent with clinical data. The appetite suppression she is already noticing by day two is physiologically plausible, and her instinct to add exercise is supported by outcome research.
Nausea is the most common side effect of liraglutide, reported in roughly 38 to 40 percent of patients in the SCALE Obesity and Prediabetes trial (Davies et al., 2015, New England Journal of Medicine). It typically peaks in the first few weeks at each dose escalation and diminishes over time. Eating small, low-fat snacks before or after injection, which is essentially what Kelly is doing, is a clinically recognized mitigation strategy. Her appetite suppression on day two is early but not implausible: liraglutide acts on GLP-1 receptors in the hypothalamus and brainstem within hours of injection, so subjective appetite changes can appear before any meaningful weight loss does.
What did they get wrong (or right)?
Kelly got the fundamentals right. She got one small detail wrong, and there is one omission worth flagging.
The arm injection is fine. All approved subcutaneous injection sites, abdomen, thigh, and upper arm, are supported in Saxenda's prescribing information. Some patients do report less discomfort in the arm, likely due to differences in subcutaneous fat depth, so her anecdotal observation is not surprising.
The omission: she does not mention rotating injection sites within each region, which matters for preventing lipohypertrophy, a localized buildup of fatty tissue that can impair drug absorption over time (Blanco et al., 2013, Diabetes Care). If she is now adding the arm to her rotation, that is actually good practice, but viewers watching this as a how-to guide would not know to vary the exact spot each time.
The hashtag misspelling of "semiglutide" instead of semaglutide is cosmetic and harmless, but worth noting: Saxenda contains liraglutide, not semaglutide. These are different GLP-1 receptor agonists with different half-lives, dosing schedules, and clinical profiles. The conflation in the hashtags could mislead viewers who are comparing medications.
What should you actually know?
A few things that Kelly's video does not cover but that anyone starting a GLP-1 should understand.
- Nausea that is manageable with snacks is normal at 0.6 mg. The standard Saxenda protocol escalates the dose monthly, and nausea tends to worsen with each increase. What is mild now may not stay mild at 1.8 mg or 3.0 mg.
- Exercise genuinely improves outcomes. A 2023 meta-analysis (Lundgren et al., 2023, Obesity Reviews) found that combining GLP-1 receptor agonist therapy with structured exercise preserved lean muscle mass better than medication alone. Kelly's instinct to jog is not just motivational content; it is clinically sound.
- Liraglutide and semaglutide are not the same drug. Saxenda is liraglutide, a once-daily injection. Semaglutide is the active ingredient in Ozempic and Wegovy, which are weekly injections with different efficacy data. Mixing up hashtags is one thing; mixing up medications is a real patient safety issue.
- "Feeling great" on day two does not predict the full experience. The dose escalation schedule exists precisely because side effects intensify. Viewers should not treat a positive day-two update as a reliable preview of the full course.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Saxenda day 2 nausea claims: what GLP-1 side effects actually look like, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Saxenda day 2 nausea claims: what GLP-1 side effects actually look like is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
Kelly is in the first week of a Saxenda (liraglutide) titration at the starting dose of 0.
FormBlends verdict
Kelly is in the first week of a Saxenda (liraglutide) titration at the starting dose of 0.6 mg daily, the lowest rung of a multi-month escalation schedule that targets 3.0 mg for weight management. She reports nausea onset consistent with the known GI side effect profile of GLP-1 receptor agonists, which is most pronounced in early titration and at each dose increase. Her plan to combine liraglutide with cardiovascular exercise is aligned with clinical guidance, as exercise during GLP-1 therapy has been associated with better preservation of lean mass during weight loss.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Kelly is in the first week of a Saxenda (liraglutide) titration at the starting dose of 0.6 mg daily, the lowest rung of a multi-month escalation schedule that targets 3.0 mg for weight management. She reports nausea onset consistent with the known GI side effect profile of GLP-1 receptor agonists, which is most pronounced in early titration and at each dose increase. Her plan to combine liraglutide with cardiovascular exercise is aligned with clinical guidance, as exercise during GLP-1 therapy has been associated with better preservation of lean mass during weight loss.
- Nausea affects roughly 38 to 40 percent of liraglutide patients in clinical trials (Davies et al., 2015, NEJM) and is most intense during dose escalation, not necessarily at the starting 0.6 mg dose.
- Small, low-fat snacks before or after injection are a recognized clinical strategy for GLP-1-associated nausea, consistent with what Kelly describes.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Nausea affects roughly 38 to 40 percent of liraglutide patients in clinical trials (Davies et al., 2015, NEJM) and is most intense during dose escalation, not necessarily at the starting 0.6 mg dose.
- Small, low-fat snacks before or after injection are a recognized clinical strategy for GLP-1-associated nausea, consistent with what Kelly describes.
- Saxenda contains liraglutide, not semaglutide. These are different drugs with different dosing schedules and efficacy data, and they should not be conflated in patient-facing content.
- A 2023 meta-analysis (Lundgren et al., Obesity Reviews) supports combining GLP-1 therapy with exercise, particularly for preserving lean muscle mass during weight loss.
- Rotating injection sites within each anatomical region, not just between regions, reduces the risk of lipohypertrophy, which can impair drug absorption over time (Blanco et al., 2013, Diabetes Care).
- A positive day-two experience at the lowest titration dose is not predictive of how a patient will tolerate higher doses. Each escalation step carries renewed nausea and GI side effect risk.
- GLP-1 receptor agonists are regulated prescription medications. Any video content about them should be understood as one person's experience, not dosing guidance or a clinical recommendation.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Kelly’s • Lifestyle • GLP1 · TikTok creator
8.8K views on this video
Day 2 on my GLP-1 journey 💉 (Saxenda 0.6 mg) feeling the nausea kick in today barley😅 but overall I’ve felt great, staying consistent and getting my workouts in. One day at a time 💪 #glp1journey #saxenda #weightlossjourney #semiglutide #glp1community
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Kelly’s • Lifestyle • GLP1, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.